News & Insights

Cases & Deals

December 7, 2022

King & Spalding Helps Get Thousands of Claims Dismissed in Zantac MDL

On December 6th, 2022, alongside counsel for codefendants, King & Spalding successfully secured a ruling that plaintiffs’ general causation experts should be excluded under FRE 702 in the federal multidistrict litigation (“MDL”) surrounding the heartburn medication ranitidine Zantac®. After excluding those experts, Judge Robin Rosenberg entered summary judgment for the defendants, ending approximately 50,000 claims against multiple defendants, including our client Boehringer Ingelheim (“BI”).

A King & Spalding team lead by Andy Bayman, Eva Canaan, Rob Friedman and Julia Zousmer represents Boehringer Ingelheim in the sprawling litigation alleging that use of Zantac caused cancer. The Wall Street Journal hailed the ruling as “a debunking for the ages” and The American Lawyer bestowed “Litigator of the Week” runner-up honors on the multiple law firms representing the defendant companies.